Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIb trial of twice-daily remogliflozin etabonate in treatment-naive patients with type 2 diabetes mellitus.

Trial Profile

Phase IIb trial of twice-daily remogliflozin etabonate in treatment-naive patients with type 2 diabetes mellitus.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Remogliflozin etabonate (Primary) ; Pioglitazone
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 23 Apr 2015 According to an Islet Sciences media release, data from this study were presented at the 50th International Liver Conference hosted by the European Association for the Study of Liver (EASL) 2015.
    • 23 Apr 2015 Results published in an Islet Sciences Media Release.
    • 14 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top